Biological E Managing Director Mahima Datla Call it a tale of two leading vaccine makers from the same city. Biological E, yet another company from Hyderabad after Bharat Biotech, is now gearing up to begin its Covid vaccine supplies. Bharat Biotech’s Covaxin was developed in collaboration with the Indian Council of Medical Research (ICMR) and … Read more
Everything about Biological E Corbevax vaccine (Representative Image, IE) Corbevax has secured permission for the third phase clinical trials of the vaccine and the government is expecting the trials to be over by July. The government has also placed an order of 300 million doses of the vaccine produced by Hyderabad -based Biological E. Here’s … Read more
Biological E’s vaccine – a RBD protein sub-unit vaccine – is currently undergoing Phase-3 clinical trials after showing promising results in phases 1 and 2. The government will make an advance payment of Rs 1,500 crore to Biological E for reserving 300 million vaccine doses. These vaccine doses will be manufactured and stockpiled by Biological … Read more
Already, the vaccines now approved and supplied by India apart from those that are to come have the potential to make a huge difference in many parts of the world. The Quad summit announcement happens at a time when the COVID-19 vaccine world is facing some of its most unique challenges. While India, which has … Read more
Paul believes that even if Pfizer vaccine will come to India, it will be after a few months, and the health department will chalk out a different strategy. After the approval for rolling out Coronavirus vaccines in the UK, Pfizer’s entry is Indian market is much more of an academic interest. It is known that … Read more
Indigenous Coronavirus vaccine candidate Covaxin, jointly developed by Bharat Biotech and the Indian Council of Medical Research (ICMR), last week entered the third phase of the Human trial. Coronavirus vaccine update: Even as coronavirus cases in some parts of the country have been witnessing a sudden spike in the past few weeks, here’s a piece … Read more